ストックスクリーナーアプリを入手
12.24
2.39%
-0.30
前日終値:
$12.54
開ける：
$12.64
24時間の取引高:
941.39K
Relative Volume:
0.86
時価総額：
$1.23B
収益：
-
当期純損益:
$-167.48M
株価収益率:
-6.2769
EPS:
-1.95
ネットキャッシュフロー:
$-197.47M
1週間 パフォーマンス:
+9.68%
1か月 パフォーマンス:
-4.30%
6か月 パフォーマンス:
-18.29%
1年 パフォーマンス:
-12.07%
1日の値動き範囲:
$12.20
$12.74
1週間の範囲:
$11.40
$12.74
52週間の値動き範囲:
$11.13
$18.07
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
名前
Day One Biopharmaceuticals Inc
セクター
電話
650 484-0899
住所
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
12.24 | 1.23B | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-09 | 繰り返されました | Needham | Buy |
| 2024-08-01 | アップグレード | BofA Securities | Underperform → Buy |
| 2024-04-24 | 繰り返されました | Needham | Buy |
| 2023-04-25 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-02-08 | 開始されました | CapitalOne | Overweight |
| 2023-02-03 | 開始されました | Oppenheimer | Perform |
| 2022-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-12-05 | 開始されました | Goldman | Buy |
| 2022-12-01 | 開始されました | BofA Securities | Buy |
すべてを表示
Day One Biopharmaceuticals Inc (DAWN) 最新ニュース
Day One Biopharmaceuticals (NASDAQ:DAWN) Issues 8-K Filing Detailing Financial Metrics and Future Milestones - Defense World
Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Analysts - Defense World
(DAWN) Technical Pivots with Risk Controls - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities - GlobeNewswire
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate - The Bakersfield Californian
Day One Biopharmaceuticals Reports Strong $57.2M Revenue for First-Year OJEMDA Sales - StockTitan
Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week Low – What’s Next? - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week LowTime to Sell? - MarketBeat
Bank of America Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $25.00 - Defense World
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5) - Seeking Alpha
Where are the Opportunities in (DAWN) - Stock Traders Daily
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Significant Decrease in Short Interest - MarketBeat
Geode Capital Management LLC Boosts Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Geode Capital Management LLC Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals: Sales Figures In The Crosshairs... And What Else? - Seeking Alpha
(DAWN) On The My Stocks Page - Stock Traders Daily
High Growth Tech Stocks to Watch in December 2024 - Simply Wall St
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $35.71 Consensus Target Price from Analysts - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Brokerages - Defense World
State Street Corp Sells 3,003 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 4,537 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Day One Biopharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference - StockTitan
Franklin Resources Inc. Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
The Children's Brain Tumor Network Partners with Day One Biopharmaceuticals to Drive New Therapies for Pediatric Brain Tumors - Marketscreener.com
Wellington Management Group LLP Acquires 423,543 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day one Biopharmaceuticals head of R&D sells $399,339 in stock - Investing.com
Charles Schwab Investment Management Inc. Acquires 64,700 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
689,655 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Purchased by Frazier Life Sciences Management L.P. - MarketBeat
Janus Henderson Group PLC Has $30.31 Million Stock Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Samsara BioCapital LLC Has $2.05 Million Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Fmr LLC Boosts Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Erste Asset Management GmbH Invests $725,000 in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Braidwell LP Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Algert Global LLC Has $996,000 Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Vestal Point Capital LP Boosts Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Brokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) PT at $35.71 - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of “Buy” by Analysts - Defense World
Dream Finders Homes Inc. (DFH) Crossed Above the 50-Day Moving Average: What That Means for Investors - MSN
Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts? - Insider Monkey
10 Best Up and Coming Stocks To Buy According to Analysts - Insider Monkey
Glioma Market Size in the 7MM is approximately USD 1,000 million in 2023, estimated DelveInsight - The Globe and Mail
What Analysts Were Expecting After Day One Biopharmaceuticals Inc (NASDAQ: DAWN) fell -2.06% - Stocks Register
When the Price of (DAWN) Talks, People Listen - Stock Traders Daily
Day One Biopharmaceuticals announces R&D leadership change By Investing.com - Investing.com Australia
Day One Biopharmaceuticals announces R&D leadership change - Investing.com India
Day One Biopharmaceuticals Inc (DAWN) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):